Clinical Trial Detail

NCT ID NCT02776917
Title Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Barbara Parker, MD
Indications

Her2-receptor negative breast cancer

Therapies

Cirmtuzumab + Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST